A dural arteriovenous fistula (dAVF) is a rare vascular condition involving an abnormal, direct connection or “short circuit” between an artery and a vein within the dura mater. The dura mater is the tough, outer membrane that covers your brain and spinal cord.
Normally, blood flows from high-pressure arteries through tiny capillaries, where nutrients and oxygen are exchanged, into low-pressure veins that return waste to the heart and lungs. In a dAVF, these capillaries are bypassed, causing arterial blood under high pressure to flow directly into the thin-walled veins. This increased pressure can lead to various neurological symptoms and potentially serious complications.
dAVFs are relatively rare, accounting for about 10-15% of all intracranial vascular malformations. They are estimated to occur in about 0.02% of the population, or 20 cases per 100,000 people per year, with increasing detection rates due to advanced imaging techniques. They tend to affect individuals between 50 and 60 years of age, though they can occur at any age, including in children.
The exact cause of dAVFs is often unclear, and in most cases, they are considered idiopathic, meaning they arise without an identifiable reason.
However, some dAVFs are associated with specific events or conditions. Current evidence suggests that many dAVFs are acquired defects that can occur in response to:
Risk factors for dAVFs include a predisposition to blood clots in the vein (vein thrombosis), which can increase the risk of venous sinus blockage or narrowing. While dAVFs are not typically genetic, hereditary disorders or recurrent trauma may predispose a patient to vascular abnormalities, potentially leading to new fistulas.
The symptoms of a dAVF can vary significantly depending on its location, size, and particularly its venous drainage pattern. Some individuals with dAVFs may not experience any symptoms, with the fistula discovered incidentally during diagnostic tests for other conditions.
Symptoms are often categorized as either benign (less serious) or aggressive (more serious):
Benign Symptoms: These are often related to increased dural sinus drainage or direct impact of the abnormal blood flow. They include:
When to see a doctor: You should make an appointment with your healthcare professional if you experience any unusual or worrying symptoms. Seek immediate medical attention if you experience a seizure or symptoms suggestive of a brain hemorrhage, such as a sudden, severe headache; nausea; vomiting; weakness or numbness on one side of the body; trouble speaking or understanding speech; vision loss or double vision; or trouble with balance.
The diagnostic process typically begins with initial imaging studies and is confirmed by a specialized procedure:
The primary goal of dAVF treatment is to stop the abnormal blood flow and close off the fistula to prevent complications. Treatment decisions are complex and often involve a multidisciplinary team of specialists, including interventional neuroradiologists, neurosurgeons, neurologists, and radiation therapists. The approach is tailored to the individual patient, considering their symptoms, the fistula’s location, size, and venous drainage pattern.
Treatment is generally indicated for dAVFs that are:
For low-risk dAVFs without cortical venous drainage and tolerable symptoms, conservative management with close follow-up may be an option, as they do not carry a risk of hemorrhage or significant neurological deficits and can sometimes spontaneously thrombose.
The main treatment modalities include endovascular embolization, surgical intervention, and radiosurgery.
Endovascular embolization is a minimally invasive procedure and is often the first-line therapeutic approach for dAVFs.
During endovascular embolization, a thin catheter is inserted into an artery, typically in your groin or wrist, and guided to the vessels supplying the dAVF under X-ray guidance. A smaller microcatheter is then positioned as close as possible to the fistula site, and an embolic agent is injected or advanced to block or “plug” the abnormal connection.
Common embolic agents include:
There are two main approaches for embolization:
The procedure is generally performed under general anesthesia.
If anesthesia or sedation is planned, you will typically need to refrain from eating or drinking for at least six hours before the procedure. If you have a history of allergies to X-ray dye, you may need to take pre-treatment medications.
While effective, embolization carries potential risks and complications, including:
Recovery time for embolization is typically shorter than for surgery. You can expect a few days of hospital monitoring, followed by a couple of weeks of rest at home. Most patients resume normal activities within a few weeks.
After the procedure, it’s normal to experience soreness, bruising, or a small lump at the puncture site for several days to weeks. You may shower the next day but should avoid soaking the puncture site (e.g., in baths, pools, or hot tubs) for about two weeks. Strenuous activity, lifting heavy objects, and exercise should be avoided for approximately five days. Some patients may feel more tired than usual for the first few weeks, which gradually improves.
Endovascular embolization has shown excellent results for dAVFs, with high obliteration (complete closure) rates. Studies report occlusion rates ranging from 80-87.5%. Symptomatic improvement, such as relief from tinnitus or ocular symptoms, is also high. An incomplete closure can lead to persistent risk of complications and new arterial feeders.
Surgical intervention is another treatment option for dAVFs, particularly when embolization alone is insufficient, the fistula is in a challenging location, or for high-risk dAVFs that need direct intervention.
During surgical resection, a neurosurgeon performs a craniotomy (temporarily removes part of your skull) to access the dAVF and carefully disconnect or remove the abnormal vessel connections. For fistulas with cortical venous drainage, the draining vein may be cauterized, and the involved dura excised.
Preoperative embolization may be performed to reduce blood loss during surgery.
Surgical treatment of dAVFs carries risks, including considerable intraoperative blood loss, venous infarction, infection, hydrocephalus (excess fluid in the brain), cerebrospinal fluid (CSF) leak, and cranial nerve palsy.
Recovery from surgery typically requires a longer hospital stay, often several days. A full recovery may take 4-6 weeks, and some patients may require physical or occupational therapy to address any lingering symptoms.
Surgical disconnection of dAVFs, especially high-grade fistulas, can be highly effective with excellent obliteration rates. However, it generally has a higher risk of morbidity and mortality compared to less invasive procedures.
Radiosurgery uses highly targeted radiation to gradually shrink and close the fistula. It is a non-invasive option, meaning no incision is made.
Stereotactic radiosurgery (SRS), such as Gamma Knife, delivers high doses of radiation precisely to the dAVF while minimizing exposure to surrounding healthy brain tissue.
Radiosurgery is an ideal approach for dAVFs that cannot be safely or effectively managed by endovascular or surgical means. It is generally not the primary treatment for dAVFs with cortical venous drainage due to the persistent risk of hemorrhage until the fistula closes.
While radiosurgery is generally effective and painless, its main limitation is that it takes months to up to 2-3 years for the fistula to fully close. During this period, the risk of hemorrhage persists. There is also a small possibility of delayed radiation after-effects.
There is no immediate recovery period after radiosurgery, as it does not involve an incision. However, follow-up imaging is necessary to track the progress of the fistula closure, and symptoms might continue until the fistula is fully treated.
Obliteration rates for dAVFs after radiosurgery are comparable to other methods, with higher success rates for cavernous sinus dAVFs or those without cortical venous reflux (around 80%). Resolution of symptoms like tinnitus and ocular issues has been reported in a high percentage of patients. Combining SRS with endovascular treatment can lead to even higher closure rates.
Regardless of the treatment method, ongoing monitoring and regular follow-up appointments are crucial after dAVF treatment. This helps healthcare providers assess the stability of the treated dAVF and monitor for any signs of recurrence.
Follow-up typically includes imaging studies, such as MRI or angiography, at intervals determined by your doctor based on your initial treatment and risk factors. It is also important for you to be vigilant for any new or returning symptoms, as early detection can lead to quicker and more effective intervention.
The survival rates for dAVF patients are generally positive, especially when the condition is diagnosed and treated early. While specific rates vary based on the fistula’s size, location, and complexity, most patients experience a high rate of treatment success. With proper treatment, many individuals experience symptom relief and can expect to lead normal, symptom-free lives.
Recurrence of a dAVF after successful treatment is relatively uncommon but not impossible. The likelihood of recurrence depends on factors like the initial treatment method, the completeness of the closure, and any underlying conditions that might predispose to new abnormal vessel formation. Regular follow-up appointments and imaging help ensure that any recurrence is detected and managed early.
Healthcare providers often use classification systems, such as the Borden Classification and the Cognard Classification, to assess the aggressiveness of dAVFs and guide treatment decisions. These systems primarily consider the venous drainage pattern as the critical factor defining the natural history and risk.
Key distinctions include:
Understanding these classifications helps your care team determine the most appropriate and timely treatment to prevent serious complications.
Dural arteriovenous fistulas are abnormal connections between arteries and veins in the brain or spinal cord’s covering. While their exact cause is often unknown, they can be acquired due to factors like head trauma or venous thrombosis. Symptoms vary from benign, like pulsatile tinnitus, to aggressive, such as bleeding in the brain or neurological deficits, depending on their location and venous drainage pattern. Diagnosis is confirmed by digital subtraction angiography. Treatment aims to close the fistula and prevent complications, typically involving endovascular embolization, surgical intervention, or radiosurgery. With early diagnosis and appropriate treatment, many patients can achieve positive outcomes and lead normal, symptom-free lives, though ongoing monitoring is essential to detect any recurrence.
